Current Report Filing (8-k)
June 27 2019 - 1:57PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
June 26, 2019
PROVECTUS
BIOPHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Delaware
|
|
001-36457
|
|
90-0031917
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
10025
Investment Drive, Suite 250, Knoxville, TN 37932
(Address
of Principal Executive Offices) (Zip Code)
(866)
594-5999
(Registrant’s
Telephone Number, Including Area Code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act: None
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.07. Submission of Matters to a Vote of Security Holders.
(a)
|
Provectus
Biopharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”)
on June 26, 2019.
|
|
|
(b)
|
At
the Annual Meeting, the Company’s stockholders voted on three proposals. A brief description and tabulation of votes
for each proposal are set forth below.
|
Proposal
1
. The Company’s stockholders elected the following directors for a term of one year at the Annual Meeting, consistent
with the recommendation of the Company’s board of directors (the “Board”). There were 232,416,468 broker non-votes
with respect to the proposal.
Name of Candidate
|
|
Number of Votes
|
|
|
|
For
|
|
|
Withhold Authority
|
|
Bruce Horowitz
|
|
|
98,623,395
|
|
|
|
3,214,702
|
|
Jan Koe
|
|
|
91,116,111
|
|
|
|
10,721,986
|
|
John Lacey, III, M.D.
|
|
|
99,504,272
|
|
|
|
2,333,825
|
|
Ed Pershing, CPA
|
|
|
98,876,545
|
|
|
|
2,961,552
|
|
Dominic Rodrigues, CFA
|
|
|
98,931,902
|
|
|
|
2,906,195
|
|
Proposal
2
. The Company’s stockholders approved the advisory vote on the compensation of the Company’s named executive
officers at the Annual Meeting, consistent with the Board’s recommendation. There were 232,416,468 broker non-votes with
respect to the proposal.
|
|
Number of Votes
|
|
For
|
|
|
95,319,312
|
|
Against
|
|
|
5,134,451
|
|
Abstention
|
|
|
1,384,334
|
|
Proposal
3
. The Company’s stockholders ratified the selection of Marcum LLP as the Company’s independent registered public
accounting firm for 2019 at the Annual Meeting, consistent with the Board’s recommendation. There were no broker non-votes
with respect to the proposal.
|
|
Number of Votes
|
|
For
|
|
|
314,877,239
|
|
Against
|
|
|
9,333,490
|
|
Abstention
|
|
|
756,621
|
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
June 27, 2019
|
PROVECTUS
BIOPHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Bruce Horowitz
|
|
|
Bruce
Horowitz
|
|
|
Chief
Operating Officer (Principal Executive Officer)
|
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From May 2023 to May 2024